PT  - JOURNAL ARTICLE
AU  - Green, W. M.
AU  - Raut, S.B.
AU  - James, F.L.J.
AU  - Benedek, D.M.
AU  - Ursano, R.J.
AU  - Johnson, L.R.
TI  - MDMA Assisted Psychotherapy Decreases PTSD Symptoms, Dissociation, Functional Disability, and Depression: A Systematic Review and Meta-Analysis
AID  - 10.1101/2023.08.17.23293955
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.08.17.23293955
4099  - http://medrxiv.org/content/early/2023/08/20/2023.08.17.23293955.short
4100  - http://medrxiv.org/content/early/2023/08/20/2023.08.17.23293955.full
AB  - Post-Traumatic Stress Disorder (PTSD) causes broad impairments affecting quality of life. However, despite current treatment many people with PTSD do not fully recover. MDMA assisted psychotherapy has emerged as a new therapy for PTSD and its comorbidities. We aimed to analyse the current evidence for MDMA assisted psychotherapy in PTSD and associated quality of life, and physiological effects, by conducting a systematic review and metanalysis of randomised controlled trials. ClinicalTrials.gov, MEDLINE, PsycINFO, PsycARTICLES, and Cochrane Library database were searched from inception to July 2022. We included both published and unpublished randomized control trials comparing MDMA assisted psychotherapy (MDMA-AP) with control. Meta-analysis of primary and secondary outcome measures was performed using Review-Manager software. Effect sizes were calculated using Standardised Mean Difference for CAPS scores and Mean Difference for secondary measures. MDMA-AP significantly improves dissociation, depression, and functional impairment, compared to controls, but not sleep quality. This data supports the use of MDMA-AP for PTSD with an improvement found in PTSD core symptoms and quality of life measures. While these findings are limited by small samples sizes in currently available clinical trials, this study provides empirical evidence to support development of MDMA-AP in PTSD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge University of Tasmania, College of Health and Medicine for funding and support. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used only openly available human data that were originally located at: 1. https://pubmed.ncbi.nlm.nih.gov/33972795/ 2.https://journals.sagepub.com/doi/full/10.1177/0269881112464827?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org 3.https://www.sciencedirect.com/science/article/abs/pii/S2215036618301354?via%3Dihub 4.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122379/ 5.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247454/ I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript